The Inflammation-Cancer Connection: What Research Reveals

In 1863, the German pathologist Rudolf Virchow noticed something that would take more than a century to fully appreciate: tumors frequently arose at sites of chronic inflammation, and cancer tissue was infiltrated with inflammatory cells. He hypothesized that cancer originated from sites of chronic irritation.

Today, we know Virchow was largely right. An estimated 15 to 25 percent of all human cancers are directly attributable to chronic inflammatory conditions or infections that produce sustained inflammation. But the relationship extends even further—inflammation influences cancer initiation, promotion, progression, and metastasis across virtually all cancer types.

How Inflammation Promotes Cancer Development

The mechanisms linking chronic inflammation to cancer are complex and operate at multiple levels:

DNA damage and mutations. Inflammatory cells, particularly activated macrophages and neutrophils, produce reactive oxygen species (ROS) and reactive nitrogen species (RNS) as part of their normal antimicrobial function. When inflammation becomes chronic, these highly reactive molecules cause oxidative damage to DNA in surrounding tissue cells. Over time, this accumulation of DNA damage increases the probability of mutations in oncogenes and tumor suppressor genes that can initiate cancer.

The NF-kB pathway. Nuclear factor kappa B (NF-kB) is a transcription factor that sits at the intersection of inflammation and cancer. When activated by inflammatory signals, NF-kB promotes the expression of genes involved in:

• Cell proliferation—driving tumor growth
• Anti-apoptosis—preventing damaged cells from dying when they should
• Angiogenesis—promoting the growth of new blood vessels to feed tumors
• Invasion and metastasis—enabling cancer cells to spread to distant sites
• Immune evasion—helping cancer cells avoid detection by the immune system

NF-kB is constitutively activated in many cancer types and is now considered one of the most important molecular links between inflammation and cancer.

The tumor microenvironment. Tumors do not exist in isolation—they create and are sustained by a complex local environment that is profoundly inflammatory. The tumor microenvironment includes immune cells (macrophages, neutrophils, T-cells), fibroblasts, blood vessels, and a soup of inflammatory cytokines and growth factors. Tumor-associated macrophages (TAMs) are particularly important: instead of attacking the tumor, they are reprogrammed by the cancer to support its growth, suppress anti-tumor immune responses, and promote metastasis.

Cancer Types Linked to Chronic Inflammation

Some of the clearest examples of inflammation-driven cancer include:

• Colorectal cancer and inflammatory bowel disease (IBD): Patients with ulcerative colitis or Crohn's disease have a significantly elevated risk of developing colorectal cancer, with risk increasing proportionally to the duration and severity of intestinal inflammation. The cumulative incidence can reach 18 percent after 30 years of disease.
• Liver cancer and hepatitis: Chronic hepatitis B and C infections cause sustained liver inflammation that drives cirrhosis and hepatocellular carcinoma. Hepatitis-related chronic inflammation accounts for approximately 80 percent of all liver cancers worldwide.
• Gastric cancer and Helicobacter pylori: The bacterium H. pylori causes chronic stomach inflammation (gastritis) and is classified as a Group 1 carcinogen by the WHO. Eradicating H. pylori infection reduces gastric cancer risk by 30 to 40 percent.
• Lung cancer and smoking/COPD: Cigarette smoke induces chronic airway inflammation. Patients with COPD, an inflammatory lung disease, have a 2 to 5 times greater risk of developing lung cancer compared to smokers without COPD, suggesting that the inflammatory component drives cancer risk independently of the direct carcinogenic effects of tobacco.
• Pancreatic cancer and chronic pancreatitis: Chronic pancreatitis, characterized by persistent pancreatic inflammation, increases the risk of pancreatic cancer by 10 to 20 fold. The inflammatory environment in the pancreas promotes the accumulation of mutations and the growth of pre-cancerous lesions.
• Cervical cancer and HPV: Human papillomavirus infection causes chronic inflammation of the cervical epithelium, which, combined with the virus's ability to disrupt tumor suppressor genes, drives the development of cervical cancer.

Inflammation and Cancer Prevention

Understanding the inflammation-cancer link has opened significant opportunities for cancer prevention:

Anti-inflammatory medications. Large epidemiological studies have consistently shown that regular aspirin use is associated with a 20 to 30 percent reduction in colorectal cancer risk. Aspirin inhibits cyclooxygenase enzymes (COX-1 and COX-2) that produce pro-inflammatory prostaglandins involved in tumor promotion. The U.S. Preventive Services Task Force has included aspirin in its colorectal cancer prevention recommendations for certain at-risk populations.

Treating underlying inflammatory conditions. Effective management of chronic inflammatory diseases—controlling IBD with anti-inflammatory therapies, eradicating H. pylori infections, vaccinating against hepatitis B—directly reduces the associated cancer risk. These interventions underscore the principle that preventing chronic inflammation prevents cancer.

Lifestyle-based inflammation reduction. The same lifestyle factors that reduce chronic inflammation also reduce cancer risk:

1. Diet: A diet rich in fruits, vegetables, whole grains, and omega-3 fatty acids reduces inflammatory biomarkers and is consistently associated with lower cancer rates. Conversely, diets high in processed meats, refined sugars, and ultra-processed foods promote inflammation and increase cancer risk.
2. Physical activity: Regular moderate exercise reduces CRP and IL-6 levels and is associated with lower rates of colon, breast, endometrial, and several other cancers. The anti-inflammatory effect of exercise is now considered a primary mechanism for this protection.
3. Weight management: Obesity is a state of chronic systemic inflammation and is an established risk factor for at least 13 types of cancer. The inflammatory cytokines produced by visceral fat create a pro-tumorigenic environment throughout the body.
4. Avoiding tobacco and excessive alcohol: Both substances cause chronic inflammation in exposed tissues and are among the strongest modifiable cancer risk factors.

The Role of Inflammation Monitoring

Given the strong link between chronic inflammation and cancer development, there is growing interest in using inflammatory biomarkers as part of cancer risk assessment and early detection strategies.

Elevated CRP levels have been associated with increased risk of several cancer types in large prospective studies, including colorectal, lung, and breast cancer. While CRP alone is not specific enough to serve as a cancer screening test, persistently elevated inflammatory markers in the context of known risk factors can provide additional clinical information.

More importantly, tracking inflammatory levels over time can help individuals assess whether their lifestyle interventions and medical treatments are actually reducing their inflammatory burden. Since the inflammation-cancer pathway typically operates over years or decades, there is a meaningful window of opportunity for intervention.

The goal is not to cause alarm, but to provide actionable data. Knowing your inflammatory status is one more piece of the puzzle in understanding and managing your long-term health risk.